| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,§
Departments of
*
Surgery,
Chemistry, and
Microbiology, The Beirne Carter Center for Immunology, and
§
Department of Pathology, University of Virginia, Charlottesville, VA 22908
To identify shared epitopes for melanoma-reactive CTL restricted by MHC molecules other than HLA-A*0201, six human melanoma patient CTL lines expressing HLA-A1 were screened for reactivity against the melanocyte differentiation proteins Pmel-17/gp100, MART-1/Melan-A, and tyrosinase, expressed via recombinant vaccinia virus vectors. CTL from five of the six patients recognized epitopes from tyrosinase, and recognition of HLA-A1+ target cells was strongly correlated with tyrosinase expression. Restriction by HLA-A1 was further demonstrated for two of those tyrosinase-reactive CTL lines. Screening of 119 synthetic tyrosinase peptides with the HLA-A1 binding motif demonstrated that nonamer, decamer, and dodecamer peptides containing the sequence KCDICTDEY (residues 243–251) all reconstituted the CTL epitope in vitro. Epitope reconstitution in vitro required high concentrations of these peptides, which was hypothesized to be a result of spontaneous modification of cysteine residues, interfering with MHC binding. Substitution of serine or alanine for the more N-terminal cysteine prevented modification at that residue and permitted target cell sensitization at peptide concentrations 2 to 3 orders of magnitude lower than that required for the wild-type peptide. Because spontaneous modification of sulfhydryl groups may also occur in vivo, tumor vaccines using this or other cysteine-containing peptides may be improved by amino acid substitutions at cysteine residues.
This article has been cited by other articles:
|
|
 |
|
  M. Ostankovitch, M. Altrich-VanLith, V. Robila, and V. H. Engelhard N-Glycosylation Enhances Presentation of a MHC Class I-Restricted Epitope from Tyrosinase J. Immunol., April 15, 2009; 182(8): 4830 - 4835. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Slingluff Jr., G. R. Petroni, K. A. Chianese-Bullock, M. E. Smolkin, S. Hibbitts, C. Murphy, N. Johansen, W. W. Grosh, G. V. Yamshchikov, P. Y. Neese, et al. Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Multipeptide Vaccines for Melanoma in the Adjuvant Setting Clin. Cancer Res., November 1, 2007; 13(21): 6386 - 6395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. Lindsey, L. Gritz, R. Sherry, A. Abati, P. A. Fetsch, L. C. Goldfeder, M. I. Gonzales, K. A. Zinnack, L. Rogers-Freezer, L. Haworth, et al. Evaluation of Prime/Boost Regimens Using Recombinant Poxvirus/Tyrosinase Vaccines for the Treatment of Patients with Metastatic Melanoma Clin. Cancer Res., April 15, 2006; 12(8): 2526 - 2537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Luiten, E. W.M. Kueter, W. Mooi, M. P.W. Gallee, E. M. Rankin, W. R. Gerritsen, S. M. Clift, W. J. Nooijen, P. Weder, W. F. van de Kasteele, et al. Immunogenicity, Including Vitiligo, and Feasibility of Vaccination With Autologous GM-CSF-Transduced Tumor Cells in Metastatic Melanoma Patients J. Clin. Oncol., December 10, 2005; 23(35): 8978 - 8991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Wettstein, N. D. Borson, J. G. Park, K. T. McNallan, and A. M. Reed Cysteine-Tailed Class I-Binding Peptides Bind to CpG Adjuvant and Enhance Primary CTL Responses J. Immunol., September 15, 2005; 175(6): 3681 - 3689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. V. Yamshchikov, D. W. Mullins, C.-C. Chang, T. Ogino, L. Thompson, J. Presley, H. Galavotti, W. Aquila, D. Deacon, W. Ross, et al. Sequential Immune Escape and Shifting of T Cell Responses in a Long-Term Survivor of Melanoma J. Immunol., June 1, 2005; 174(11): 6863 - 6871. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Dieckmann, E. S. Schultz, B. Ring, P. Chames, G. Held, H. R. Hoogenboom, and G. Schuler Optimizing the exogenous antigen loading of monocyte-derived dendritic cells Int. Immunol., May 1, 2005; 17(5): 621 - 635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Slingluff Jr, G. R. Petroni, G. V. Yamshchikov, S. Hibbitts, W. W. Grosh, K. A. Chianese-Bullock, E. A. Bissonette, D. L. Barnd, D. H. Deacon, J. W. Patterson, et al. Immunologic and Clinical Outcomes of Vaccination With a Multiepitope Melanoma Peptide Vaccine Plus Low-Dose Interleukin-2 Administered Either Concurrently or on a Delayed Schedule J. Clin. Oncol., November 15, 2004; 22(22): 4474 - 4485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tsukahara, Y. Nabeta, S. Kawaguchi, H. Ikeda, Y. Sato, K. Shimozawa, K. Ida, H. Asanuma, Y. Hirohashi, T. Torigoe, et al. Identification of Human Autologous Cytotoxic T-Lymphocyte-Defined Osteosarcoma Gene That Encodes a Transcriptional Regulator, Papillomavirus Binding Factor Cancer Res., August 1, 2004; 64(15): 5442 - 5448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Savage, L. Gao, K. Vento, P. Cowburn, S. Man, N. Steven, G. Ogg, A. McMichael, A. Epenetos, E. Goulmy, et al. Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen Blood, June 15, 2004; 103(12): 4613 - 4615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Sasada, H. Takedatsu, K. Azuma, M. Koga, Y. Maeda, S. Shichijo, H. Shoumura, T. Hirai, A. Takabayashi, and K. Itoh Immediate Early Response Gene X-1, a Stress-Inducible Antiapoptotic Gene, Encodes Cytotoxic T-Lymphocyte (CTL) Epitopes Capable of Inducing Human Leukocyte Antigen-A33-Restricted and Tumor-Reactive CTLs in Gastric Cancer Patients Cancer Res., April 15, 2004; 64(8): 2882 - 2888. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Purcell and J. J. Gorman Immunoproteomics: Mass Spectrometry-based Methods to Study the Targets of the Immune Response Mol. Cell. Proteomics, March 1, 2004; 3(3): 193 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Harada, R. Gohara, S. Matsueda, A. Muto, T. Oda, Y. Iwamoto, and K. Itoh In Vivo Evidence That Peptide Vaccination Can Induce HLA-DR-Restricted CD4+ T Cells Reactive to a Class I Tumor Peptide J. Immunol., February 15, 2004; 172(4): 2659 - 2667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Slingluff Jr, G. R. Petroni, G. V. Yamshchikov, D. L. Barnd, S. Eastham, H. Galavotti, J. W. Patterson, D. H. Deacon, S. Hibbitts, D. Teates, et al. Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic Cells J. Clin. Oncol., November 1, 2003; 21(21): 4016 - 4026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Reynolds, A. Zeleniuch-Jacquotte, R. L. Shapiro, D. F. Roses, M. N. Harris, D. Johnston, and J.-C. Bystryn Vaccine-induced CD8+ T-cell Responses to MAGE-3 Correlate with Clinical Outcome in Patients with Melanoma Clin. Cancer Res., February 1, 2003; 9(2): 657 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Haque, P. Li, S. K. Jackson, H. M. Zarour, J. W. Hawes, U. T. Phan, M. Maric, P. Cresswell, and J. S. Blum Absence of {gamma}-Interferon-inducible Lysosomal Thiol Reductase in Melanomas Disrupts T Cell Recognition of Select Immunodominant Epitopes J. Exp. Med., May 20, 2002; 195(10): 1267 - 1277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Akilesh, M. E. Dudley, P. A. Eden, and D. C. Roopenian Efficient Chromosomal Mapping of a Methylcholanthrene- Induced Tumor Antigen by CTL Immunoselection J. Immunol., November 1, 2001; 167(9): 5143 - 5149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Haque, J. W. Hawes, and J. S. Blum Cysteinylation of MHC Class II Ligands: Peptide Endocytosis and Reduction Within APC Influences T Cell Recognition J. Immunol., April 1, 2001; 166(7): 4543 - 4551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Zarling, S. B. Ficarro, F. M. White, J. Shabanowitz, D. F. Hunt, and V. H. Engelhard Phosphorylated Peptides Are Naturally Processed and Presented by Major Histocompatibility Complex Class I Molecules in Vivo J. Exp. Med., December 18, 2000; 192(12): 1755 - 1762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nishizaka, S. Gomi, K. Harada, K. Oizumi, K. Itoh, and S. Shichijo A New Tumor-Rejection Antigen Recognized by Cytotoxic T Lymphocytes Infiltrating into a Lung Adenocarcinoma Cancer Res., September 1, 2000; 60(17): 4830 - 4837. [Abstract] [Full Text]
|
|
|
|
|
|
S. Gomi, M. Nakao, F. Niiya, Y. Imamura, K. Kawano, S. Nishizaka, A. Hayashi, Y. Sobao, K. Oizumi, and K. Itoh A Cyclophilin B Gene Encodes Antigenic Epitopes Recognized by HLA-A24-Restricted and Tumor-Specific CTLs J. Immunol., November 1, 1999; 163(9): 4994 - 5004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Drexler, E. Antunes, M. Schmitz, T. Wolfel, C. Huber, V. Erfle, P. Rieber, M. Theobald, and G. Sutter Modified Vaccinia Virus Ankara for Delivery of Human Tyrosinase as Melanoma-associated Antigen: Induction of Tyrosinase- and Melanoma-specific Human Leukocyte Antigen A*0201-restricted Cytotoxic T Cells in Vitro and in Vivo Cancer Res., October 1, 1999; 59(19): 4955 - 4963. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Valmori, M. J. Pittet, C. Vonarbourg, D. Rimoldi, D. Lienard, D. Speiser, R. Dunbar, V. Cerundolo, J.-C. Cerottini, and P. Romero Analysis of the Cytolytic T Lymphocyte Response of Melanoma Patients to the Naturally HLA-A*0201-associated Tyrosinase Peptide 368-376 Cancer Res., August 1, 1999; 59(16): 4050 - 4055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Yang, M. Nakao, S. Shichijo, T. Sasatomi, H. Takasu, H. Matsumoto, K. Mori, A. Hayashi, H. Yamana, K. Shirouzu, et al. Identification of a Gene Coding for a Protein Possessing Shared Tumor Epitopes Capable of Inducing HLA-A24-restricted Cytotoxic T Lymphocytes inCancer Patients Cancer Res., August 1, 1999; 59(16): 4056 - 4063. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Rohrer, A. L. Barsoum, D. L. Dyess, J. A. Tucker, and J. H. Coggin Jr. Human Breast Carcinoma Patients Develop Clonable Oncofetal Antigen-Specific Effector and Regulatory T Lymphocytes J. Immunol., June 1, 1999; 162(11): 6880 - 6892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Castelli, P. Tarsini, A. Mazzocchi, F. Rini, L. Rivoltini, F. Ravagnani, F. Gallino, F. Belli, and G. Parmiani Novel HLA-Cw8-Restricted T Cell Epitopes Derived from Tyrosinase-Related Protein-2 and gp100 Melanoma Antigens J. Immunol., February 1, 1999; 162(3): 1739 - 1748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kawakami, P. F. Robbins, X. Wang, J. P. Tupesis, M. R. Parkhurst, X. Kang, K. Sakaguchi, E. Appella, and S. A. Rosenberg Identification of New Melanoma Epitopes on Melanosomal Proteins Recognized by Tumor Infiltrating T Lymphocytes Restricted by HLA-A1, -A2, and -A3 Alleles J. Immunol., December 15, 1998; 161(12): 6985 - 6992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Hudrisier, J. Riond, H. Mazarguil, and J. E. Gairin Pleiotropic Effects of Post-translational Modifications on the Fate of Viral Glycopeptides as Cytotoxic T Cell Epitopes J. Biol. Chem., October 5, 2001; 276(41): 38255 - 38260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Jager, S. Gnjatic, Y. Nagata, E. Stockert, D. Jager, J. Karbach, A. Neumann, J. Rieckenberg, Y.-T. Chen, G. Ritter, et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers PNAS, October 24, 2000; 97(22): 12198 - 12203. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
